Drug Withdrawal in the USA and EU: A Comparative Regulatory Review with Case-Based Evidence

The procedure by which the FDA revokes permission for a New Drug Application   (NDA) or abbreviated application (ANDA), or when a sponsor voluntarily withdraws it, is known as a drug application withdrawal. This happens when a medication is thought to be dangerous, ineffective, or when the application contains inaccurate information.
The FDA may revoke clearance in accordance with 21 CFR 314.150 if data indicates a medication is dangerous, ineffective, or the maker has broken compliance regulations.
When a pharmaceutical product's benefit-risk ratio turns negative, it gets removed off the market. This process is known as drug withdrawal. Even though pharmaceuticals go through a rigorous pre-clinical and clinical screening process before being approved, some side effects might not show up until they are widely used by the general public. Regulatory bodies step in to safeguard the public's health in these circumstances by imposing safety warnings, limitations, product recalls, or total product withdrawal.
In the past, a number of medication safety accidents have had a major impact on global regulations. The Thalidomide catastrophe of the early 1960s, in which the medication—originally used as a sedative and to alleviate morning sickness during pregnancy—was connected to severe congenital deformities in thousands of newborns, is among the most prominent cases. This incident increased regulatory control in numerous nations and resulted in significant changes to drug approval and monitoring systems. According to the data, the number of FDA withdrawal letters for safety or effectiveness concerns rose steadily between 1994 and 2024, peaking between 2010 and 2014. The number of actual application withdrawals, on the other hand, stayed comparatively low throughout the course of the time, suggesting that withdrawal letters rather than full application withdrawals were used to address the majority of regulatory issues.

Figure 1. FDA withdrawal notices and application withdrawals from 1994 to 2024 for reasons related to safety or efficacy

Figure 2. illustrates the trend analysis of European Medicines Agency (EMA) regulatory data from 1995 to 2023. It reveals that withdrawal notices gradually increased in the early years, peaked between 2010 and 2012, and then fluctuated somewhat in subsequent years. The majority of regulatory issues are found and resolved during the evaluation process prior to final authorization, as evidenced by the continuously low number of real application withdrawals brought on by safety or efficacy concerns—roughly one to three cases annually.

Figure 2. The EMA (1995–2023) documented a trend of withdrawal warnings and withdrawals of marketing authorization applications due to safety or effectiveness concerns.

Due to severe adverse drug reactions such hepatotoxicity, cardiotoxicity, and other potentially fatal disorders, many drugs have been discontinued worldwide. Effective pharmacovigilance systems are crucial since studies show that safety concerns continue to be the primary reason for drug discontinuation. The U.S. Food and Drug Administration is in charge of monitoring drug safety and making withdrawal decisions in the country. The European Medicines Agency and member state national regulatory bodies oversee comparable regulatory duties throughout the EU. While safeguarding patient safety is a common goal of both regulatory regimes, there are variations in post-marketing risk assessment methods, timetables, and regulatory processes. The table contrasts the pharmacovigilance systems of the European Medicines Agency and the U.S. Food and Drug Administration, emphasizing significant variations in safety monitoring procedures, adverse event reporting systems, and post-marketing drug safety regulations.

Table 1. A comparative analysis of the pharmacovigilance systems used by the European Medicines Agency (EMA) and the US Food and Drug Administration (USFDA).

This review, which is backed by case-based evidence of medications that were discontinued because of serious safety issues, thus focuses on contrasting the drug withdrawal procedures in the US and the EU.

MATERIALS AND METHODS:

Method for Searching Literature: To find pertinent research on medication withdrawal and regulatory frameworks, a thorough literature search was carried out. Peer-reviewed publications were found by searching scientific databases such as PubMed, Scopus, and Google Scholar. Additionally, the websites of the European Medicines Agency and the U.S. Food and Drug Administration provided official safety communications, reports, and regulatory recommendations. Drug withdrawal, marketing authorization withdrawal, pharmacovigilance, drug safety, regulatory guidelines, and post-marketing surveillance were among the search terms used.

Search Period: The review's material was produced between 2000 and 2024, which made it possible to examine current pharmacovigilance procedures and regulatory changes pertaining to drug withdrawal.

RESULTS:

 Overview of Drug withdrawal causes

Table 2. Common Causes of Drug Withdrawal with Representative Examples.

Drug Withdrawal Framework in the United States

The Federal Food, Drug, and Cosmetic Act (FD&C Act) gives the U.S. Food and Drug Administration the power to revoke the approval of a pharmaceutical product in the United States. The FDA may revoke approval of a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) in accordance with 21 CFR 314.150 if there is strong evidence that the medication no longer satisfies the necessary safety, efficacy, or quality requirements. A drug's approval may be revoked for a number of reasons, such as proof that the drug is unsafe under the conditions of use specified in the labeling, new clinical or scientific data showing a lack of therapeutic effectiveness, submission of false or misleading information in the original application, noncompliance with post-marketing safety reporting requirements, manufacturing flaws affecting the drug product's quality, purity, or strength, misleading labeling that is not corrected within a specified period, noncompliance with Good Laboratory Practice or ethical standards in clinical investigations, and failure to submit the necessary bioavailability or bioequivalence data. In compliance with 21 CFR 314.200, the FDA typically offers the application holder a hearing before starting the withdrawal process. Regulatory assessment of safety signals, analysis of scientific data, and assessment of the medication's overall benefit-risk balance are all part of the withdrawal process (Fig. 3.2).

Figure 3. FDA withdrawal procedure for drug applications.

When a medicine poses an immediate risk to public health, the FDA may suspend approval right away and give the sponsor an accelerated hearing. Additionally, if an approved medication is no longer marketed or if safety issues surface during post-marketing surveillance, pharmaceutical makers may voluntarily request that it be withdrawn. When serious hazards to patient safety are found, the FDA may also advise voluntary market withdrawal.

Drug Withdrawal Framework in the European Union

The European Medicines Agency works with national competent authorities of the member states to coordinate regulatory processes for the approval and withdrawal of pharmaceuticals within the European Union. At any point during the examination process, applicants may withdraw a marketing authorization application under the centralized authorization system by formally notifying the Agency and offering an explanation. The EMA makes information about withdrawn applications publicly available in order to encourage openness. Applications may be withdrawn for a number of reasons, such as inadequate clinical evidence of efficacy, new safety concerns, poor quality paperwork, or the applicant's strategic choices. Article 11 of Regulation (EC) No. 726/2004, which mandates that applicants notify the EMA of the reasons for withdrawal, provides the legal foundation for disseminating information about withdrawn applications. Once commercially secret information has been removed, the Agency may also publish the associated assessment reports. In September 2006, the European Medicines Agency (EMA) broadened its transparency policy under Article 80 of Regulation (EC) No. 726/2004 to cover withdrawals pertaining to modifications meant to extend therapeutic indications, including situations that arise following the adoption of an opinion by the Committee for Medicinal Products for Human Use but prior to a final decision by the European Commission. In order to provide transparency while safeguarding sensitive information, regulatory papers are published in accordance with EMA guidelines on the identification and redaction of secret information that were approved in March 2012.

Figure 4. EMA drug application withdrawal process

Comparative Analysis of Drug Withdrawal Systems

Table 3. Comparative analysis of drug application withdrawal between USFDA and EMA system

Case Studies of Withdrawn Drugs

Table 4. Case Studies of Withdrawn Drugs

Selected instances of pharmaceutical items that were banned or withdrawn in various nations because of safety issues, insufficient therapeutic efficacy, or an unfavorable risk-benefit profile are included in the table. In order to ensure patient safety and regulatory control, these cases demonstrate the significance of post-marketing surveillance and pharmacovigilance systems in discovering major adverse effects that might not be fully recognized during pre-approval clinical trials.

DISCUSSION: Comparing the regulatory regimes in the US and the EU reveals both parallels and divergences in how they handle market withdrawals and drug safety. To find safety signals and reevaluate the risk-benefit profile of licensed medications, both systems heavily rely on post-marketing pharmacovigilance data. When safety concerns emerge, the U.S. Food and Drug Administration has the clear legal authority to suspend or revoke drug approvals under a centralized regulatory framework. The European Medicines Agency, on the other hand, collaborates with national responsible authorities of EU member states, which may have an impact on regulatory deadlines and decision-making procedures. Both regulatory regimes place a high priority on patient safety despite these procedural variations. When the benefit-risk ratio turns unfavorable, they employ regulatory tools like safety alerts, labeling changes, and market withdrawal.

Table 5. Comparative regulatory aspects.